Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status
出版年份 2015 全文链接
标题
Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status
作者
关键词
Dedifferentiated thyroid carcinoma, Sorafenib, Multi-kinase inhibitor, Molecular targeted therapy, BRAF mutation, MAP kinase
出版物
BMC CANCER
Volume 15, Issue 1, Pages -
出版商
Springer Nature
发表日期
2015-03-26
DOI
10.1186/s12885-015-1186-0
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Association Between BRAF V600E Mutation and Recurrence of Papillary Thyroid Cancer
- (2015) Mingzhao Xing et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
- (2014) Marcia S Brose et al. LANCET
- Sorafenib enhances proteasome inhibitor-induced cell death via inactivation of Akt and stress-activated protein kinases
- (2013) Yuichi Honma et al. JOURNAL OF GASTROENTEROLOGY
- A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers
- (2012) Stephanie M. Cohen et al. AMERICAN JOURNAL OF SURGERY
- Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways
- (2012) Su Jung Oh et al. ENDOCRINE-RELATED CANCER
- Sorafenib attenuates monocrotaline-induced sinusoidal obstruction syndrome in rats through suppression of JNK and MMP-9
- (2012) Kojiro Nakamura et al. JOURNAL OF HEPATOLOGY
- Phase II Trial of Sorafenib in Patients with Advanced Anaplastic Carcinoma of the Thyroid
- (2012) Panayiotis Savvides et al. THYROID
- New treatment modalities in advanced thyroid cancer
- (2011) E. Kapiteijn et al. ANNALS OF ONCOLOGY
- Rationale and design of DECISION: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer
- (2011) Marcia S Brose et al. BMC CANCER
- Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population
- (2011) Merina Ahmed et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- ENDOCRINE TUMOURS: Approach to the patient with advanced differentiated thyroid cancer
- (2011) M Schlumberger et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Treatment with Tyrosine Kinase Inhibitors for Patients with Differentiated Thyroid Cancer: the M. D. Anderson Experience
- (2010) Maria E. Cabanillas et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Mitochondrial Localization and Regulation of BRAFV600Ein Thyroid Cancer: A Clinically Used RAF Inhibitor Is Unable to Block the Mitochondrial Activities of BRAFV600E
- (2010) Min Hee Lee et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations
- (2009) Ana Preto et al. BMC CANCER
- Caspase activation pathways: some recent progress
- (2009) S P Cullen et al. CELL DEATH AND DIFFERENTIATION
- Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma
- (2009) Hendrieke Hoftijzer et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Advances in Chemotherapy of Differentiated Epithelial and Medullary Thyroid Cancers
- (2009) Steven I. Sherman JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Phase II Trial of Sorafenib in Metastatic Thyroid Cancer
- (2009) Richard T. Kloos et al. JOURNAL OF CLINICAL ONCOLOGY
- Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies
- (2008) Robert C Smallridge et al. ENDOCRINE-RELATED CANCER
- Cytogenetical observations in five human anaplastic thyroid carcinomas
- (2008) JOACHIM MARK et al. HEREDITAS
- Deoxyribonucleic Acid Profiling Analysis of 40 Human Thyroid Cancer Cell Lines Reveals Cross-Contamination Resulting in Cell Line Redundancy and Misidentification
- (2008) Rebecca E. Schweppe et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Phase II Trial of Sorafenib in Advanced Thyroid Cancer
- (2008) Vandana Gupta-Abramson et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical implications of BRAF mutation in thyroid carcinoma
- (2008) Efisio Puxeddu et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now